Delivery systems to increase the selectivity of antibiotics in phagocytic cells

被引:163
作者
Briones, Elsa [1 ]
Colino, Clara Isabel [1 ]
Lanao, Jose M. [1 ]
机构
[1] Univ Salamanca, Fac Pharm, Dept Pharm & Pharmaceut Technol, Salamanca 37007, Spain
关键词
delivery systems; antibiotics; phagocytic cells; intracellular infections; selectivity;
D O I
10.1016/j.jconrel.2007.10.027
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Many infectious diseases are caused by facultative organisms that are able to survive in phagocytic cells. The intracellular location of these microorganisms protects them from the host defence systems and from some antibiotics with poor penetration into phagocytic cells. One strategy used to improve the penetration of antibiotics into phagocytic cells is the use of carrier systems that deliver these drugs directly to the target cell. Delivery systems such as liposomes, micro/nanoparticles, lipid systems, conjugates, and biological carriers such as erythrocyte ghosts may contribute to increasing the therapeutic efficacy of antibiotics and antifungal agents in the treatment of infections caused by intracellular microorganisms. The main objective of this review is to analyze recent advances and current perspectives in the use of antibiotic delivery systems in the treatment of intracellular infections such as mycobacterial infections, brucellosis, salmonellosis, lysteriosis, fungal infections, visceral leishmaniasis, and HIV (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:210 / 227
页数:18
相关论文
共 210 条
[41]   Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats [J].
Echevarría, I ;
Barturen, C ;
Renedo, MJ ;
Trocóniz, IF ;
Dios-Viéitez, MC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :898-904
[42]   INVIVO CLEARANCE OF ANTIBODY-SENSITIZED HUMAN DRUG CARRIER ERYTHROCYTES [J].
EICHLER, HG ;
GASIC, S ;
BAUER, K ;
KORN, A ;
BACHER, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (03) :300-303
[43]   Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients [J].
Eldem, T ;
Arican-Cellat, N ;
Agabeyoglu, I ;
Akova, M ;
Kansu, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 213 (1-2) :153-161
[44]   Evaluation of cationic solid lipid microparticles as synthetic carriers for the targeted delivery of macromolecules to phagocytic antigen-presenting cells [J].
Erni, C ;
Suard, C ;
Freitas, S ;
Dreher, D ;
Merkle, HP ;
Walter, E .
BIOMATERIALS, 2002, 23 (23) :4667-4676
[45]  
Ernst JD, 2006, ADV M C M, P246, DOI 10.1017/CBO9780511541513.008
[46]   Polymeric carriers for amphotericin B:: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice [J].
Espuelas, MS ;
Legrand, P ;
Campanero, MA ;
Appel, M ;
Chéron, M ;
Gamazo, C ;
Barratt, G ;
Irache, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (03) :419-427
[47]   A novel injectable water-soluble amphotericin B-arabinogalactan conjugate [J].
Falk, R ;
Domb, AJ ;
Polacheck, I .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1975-1981
[48]   SUCCESSFUL TREATMENT USING GENTAMICIN LIPOSOMES OF SALMONELLA-DUBLIN INFECTIONS IN MICE [J].
FIERER, J ;
HATLEN, L ;
LIN, JP ;
ESTRELLA, D ;
MIHALKO, P ;
YAUYOUNG, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (02) :343-348
[49]   Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells [J].
Filion, MC ;
Phillips, NC .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1997, 1329 (02) :345-356
[50]   A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus [J].
Franchetti, P ;
Abu Sheikha, G ;
Cappellacci, L ;
Marchetti, S ;
Grifantini, M ;
Balestra, E ;
Perno, CF ;
Benatti, U ;
Brandi, G ;
Rossi, L ;
Magnani, M .
ANTIVIRAL RESEARCH, 2000, 47 (03) :149-158